since you bragged about your most recent fake short trade.. Remember? You bragged that you caught another high of 358? Just before that you bragged that you caught another winning short at 346? Now the IBB is 364. Remember the smart money was shorting the IBB 25 points ago? You were part of the smart money. And we were all muppets... When will you admit you covered and that your scrotam is splattered on the tile?
alright, not 75K every day this month... How about 300K since March 1... Read my posts my friend...You will learn something... Your strategy of the put call stay in the same range is one that means you are not using my strategy of only long calls in the sickest biotech bull market of all time.. Did you use that strategy on ICPT, while I was purchasing the June 200's at 11 bucks?
the shorts are just getting hammered... Dolo is right,,, this is some crazy bubble... Im making like 75K a day on all of my holdings... a day... But its so much fun to hold...No one wants to be the last one standing in this market, but the fun could last another year... Low rates= more fun for longs....
Another important development is that two abstracts we recently submitted have been accepted for presentation on March 20 at the AASLD colloquium in North Carolina. Both abstracts are new subgroup analyses of the FLINT trial data we performed following receipt of the full data sets last year and provide important new insights on the efficacy and safety of OCA in NASH patients. One abstract is focused on the histologic improvements associated with OCA treatment in the designated breakthrough population of NASH patients with fibrosis who are at higher risk of progression to cirrhosis.
The second is focused on the impact of OCA on key cardio-metabolic safety parameters and provides subgroup analyses showing the impact on LDL-cholesterol with concomitant statin use in patients receiving OCA. We're excited to share these new data with the medical community since these important analyses were not included in the original Lancet publication.
if you read the transcript of the earnings conference call, the ceo brags about how positive this data is... He basically says that the subset analysis of patients illustrate that there is zero cardiac risk. Essentially he is putting the cardiac side affects solely in the camp of not being a result of the drug, imo....do your own due diligence though....
Dolo hit it again! lol, keeps thinking he hit the top and then it rolls down after his magical trade, and then 2 days later, he hits it a few more points higher... This guy is shrewd!
good work. How many pretend trades do you make a day? You never answered me, How much smart money do you have invested in this postion? The muppets would like to know..., sir.